Literature DB >> 10741717

Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.

M Motwani1, X Li, G K Schwartz.   

Abstract

Defects in cell cycle checkpoints can lead to chromosome abnormality, aneuploidy, and genomic instability, all of which can contribute to tumorigenesis. Recent studies and data presented in this study indicate that cells with compromised G1 checkpoint endoreduplicate and become polyploid in response to microtubule inhibitors. Previous studies have shown that polyploid cells are unstable and lose chromosomes randomly to give aneuploidy. In this study, we show that endoreduplication and polyploidation can be prevented by inhibiting the cyclin-dependent kinases (Cdks) by flavopiridol, a synthetic flavone presently undergoing phase II clinical trials. In our initial studies, we treated MCF-7 cells with paclitaxel, which results in the arrest of cells in G1 with 4n DNA content (pseudo G1). This was coincident with increased p53 and p21 protein expression and decreased cyclin E/Cdk2 kinase activity. In contrast, G1 checkpoint-compromised MDA-MB-468 (p53-/- and pRb-/-) and p21-/- HCT116 do not arrest in the pseudo G1 state after exposure to microtubule inhibitors and enter in the S phase with 4n DNA content. More than 60% of MDA-MB-468 cells accumulate with >4n DNA content after 72 h of nocodazole treatment. The MPM-2 labeling showed that 8n cells also undergo mitosis. These cells display deregulated and persistent activation of cyclin E/Cdk2 and cyclin B1/cdc2 kinase activity. Administration of flavopiridol after mitotic block results in the arrest of cells in the pseudo G1 state and the dramatic decrease in cells containing >4n DNA content in MDA-MB-468 cells. The cyclin E/Cdk2 and cyclin B1/cdc2 kinase activities remained low after exit from mitosis. Furthermore, pRb was hypophosphorylated after the addition of flavopiridol in p21-deficient HCT116 cells, indicating the arrest of cells at the pseudo G1 state. Based on these studies, we propose that flavopiridol preserves the genomic stability by preventing endoreduplication and polyploidy and thus has the potential to be used as a chemopreventive agent to prevent the occurrence of neoplasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741717

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Authors:  Jayasree S Nair; Alan L Ho; Archie N Tse; Jesse Coward; Haider Cheema; Grazia Ambrosini; Nicholas Keen; Gary K Schwartz
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

Review 2.  Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.

Authors:  Chinthalapally V Rao; Mudassir Farooqui; Adam S Asch; Hiroshi Y Yamada
Journal:  Cell Cycle       Date:  2018-09-20       Impact factor: 4.534

3.  Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.

Authors:  Deepika Rajesh; H Ian Robins; Steven P Howard
Journal:  J Neurol Neuromedicine       Date:  2016

4.  Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.

Authors:  Martin L Miller; Evan J Molinelli; Jayasree S Nair; Tahir Sheikh; Rita Samy; Xiaohong Jing; Qin He; Anil Korkut; Aimee M Crago; Samuel Singer; Gary K Schwartz; Chris Sander
Journal:  Sci Signal       Date:  2013-09-24       Impact factor: 8.192

5.  Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.

Authors:  B J Passer; P Castelo-Branco; J S Buhrman; S Varghese; S D Rabkin; R L Martuza
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

6.  Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.

Authors:  C M Galmarini; N Falette; E Tabone; C Levrat; R Britten; N Voorzanger-Rousselot; O Roesch-Gateau; A Vanier-Viornery; A Puisieux; C Dumontet
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

7.  Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.

Authors:  Ilaria Lorenzon; Ilenia Pellarin; Ilenia Pellizzari; Sara D'Andrea; Barbara Belletti; Maura Sonego; Gustavo Baldassarre; Monica Schiappacassi
Journal:  Cells       Date:  2019-12-21       Impact factor: 6.600

8.  Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.

Authors:  Mary M Heckler; Tizita Zewde Zeleke; Shailaja D Divekar; Aileen I Fernandez; Deanna M Tiek; Jordan Woodrick; Alexander Farzanegan; Rabindra Roy; Aykut Üren; Susette C Mueller; Rebecca B Riggins
Journal:  Oncotarget       Date:  2016-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.